About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 15 record(s)
Req # A-2023-000008
The most recent draft copy of the State of Per and Polyfluoroalkyl Substances (PFAS) Report being prepared by Health Canada.Organization: Health Canada
September 2023
Req # A-2021-001603
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the cover letter from the drug sponsor.Organization: Health Canada
April 2022
Req # A-2021-001600
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the proposed Certified Product Information Document.Organization: Health Canada
February 2022
Req # A-2021-001601
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the “Batch Formula” (3.2.P.3.2).Organization: Health Canada
February 2022
Req # A-2021-001602
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the “Description of Manufacturing Process and Process Controls” (3.2.P.3.3).Organization: Health Canada
February 2022
Req # A-2021-001605
For the Abbreviated New Drug Submission underlying the generic submission under review containing the medicinal ingredient “trabectedin”, provide the proposed Product Monograph.Organization: Health Canada
February 2022
Req # A-2020-000953
The list of the number of registration certificates authorizing the production of Cannabis for personal possession and/or for medical use in the City of Saint-Colomban area.Organization: Health Canada
November 2020
Req # A-2020-000059
In relation to the Non-Insured Health Benefits Program (the “NIHB”), all final letters, memoranda, memoranda to Cabinet, briefing notes, strategic plans, data/analyses, reports/evaluations, opinions or agreements (including funding agreements),Organization: Health Canada
September 2020
Req # A-2019-001561
A record which indicates whether the 2 octreotide acetate submissions posted on the Generic Submissions Under Review (GSUR) listing pertain to a single manufacturer or not.Organization: Health Canada
March 2020
Req # A-2019-000740
All documents submitted by Sandoz Canada Inc. in Electronic Common Technical Document (eCTD) Module 1.6.1 (Comparative Bioavailability Information) of any Abbreviated New Drug Submissions made by Sandoz Canada Inc. for its GLATOPA product (glatiramer acetate).Organization: Health Canada
February 2020